Literature DB >> 19191005

PKU-what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders.

F J van Spronsen1, K Kiaer Ahring, M Gizewska.   

Abstract

BACKGROUND: Since the start of the European Society of Phenylketonuria and Allied Disorders Treated as Phenylketonuria (ESPKU) in 1987, an increasing number of parental organizations of member countries have joined. Treatment varies widely within Europe. A survey among professionals was done to determine goals and practice.
METHOD: In 2005, a questionnaire was sent to professionals of member countries, addressing diagnostic and treatment procedures, numbers of patients necessary for a PKU centre, guidelines followed, numbers of patients treated and professionals involved in care, target phenylalanine concentrations, amount of protein prescribed, frequency of monitoring and clinical visits, need for follow-up of various clinical and biochemical data, the importance of various abnormalities, and definition of (non)compliance.
RESULTS: Seventeen centres of 12 countries answered. Professionals of 13 countries could not be reached or did not respond. Differences in care were observed in many issues of care including target phenylalanine concentrations. Only few issues had general consensus.
CONCLUSION: Not all countries were really active at ESPKU level. In the active countries, a professional could not always be contacted. Responses show that PKU care varies largely between European countries. Notwithstanding the large diversity on many issues of day-to-day care and therapeutic targets, results showed increasing consensus on some issues. The most important outcome of this questionnaire might be that the Scientific Advisory Committee of the ESPKU initiated meetings for professionals of different backgrounds taking care of PKU patients besides the already existing programme for parents, patients and delegates. Discussion among these professionals may improve quality of care.

Entities:  

Mesh:

Year:  2009        PMID: 19191005     DOI: 10.1007/s10545-008-0966-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  Vitamin B12 deficiency in adolescents and young adults with phenylketonuria.

Authors:  W B Hanley; A Feigenbaum; J T Clarke; W Schoonheyt; V Austin
Journal:  Lancet       Date:  1993-10-16       Impact factor: 79.321

2.  Survey of national guidelines for the treatment of phenylketonuria.

Authors:  S Schweitzer-Krantz; P Burgard
Journal:  Eur J Pediatr       Date:  2000-10       Impact factor: 3.183

3.  Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study.

Authors:  P Burgard; F Rey; A Rupp; V Abadie; J Rey
Journal:  Pediatr Res       Date:  1997-03       Impact factor: 3.756

Review 4.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

5.  Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria.

Authors: 
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

Review 6.  Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria.

Authors: 
Journal:  BMJ       Date:  1993-01-09

7.  Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care.

Authors:  Carol S Camfield; Marissa Joseph; Teresa Hurley; Karen Campbell; Susan Sanderson; Peter R Camfield
Journal:  J Pediatr       Date:  2004-07       Impact factor: 4.406

8.  Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997.

Authors:  P Burgard; H J Bremer; P Bührdel; P C Clemens; E Mönch; H Przyrembel; F K Trefz; K Ullrich
Journal:  Eur J Pediatr       Date:  1999-01       Impact factor: 3.183

9.  How practical are recommendations for dietary control in phenylketonuria?

Authors:  J H Walter; F J White; S K Hall; A MacDonald; G Rylance; A Boneh; D E Francis; G J Shortland; M Schmidt; A Vail
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  9 in total
  18 in total

1.  New insights in growth of phenylketonuric patients.

Authors:  María L Couce; Ipek Guler; Andrés Anca-Couce; Marta Lojo; Alicia Mirás; Rosaura Leis; Alejandro Pérez-Muñuzuri; José M Fraga; Francisco Gude
Journal:  Eur J Pediatr       Date:  2014-11-01       Impact factor: 3.183

Review 2.  Newborn blood spot screening: new opportunities, old problems.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2009-05-04       Impact factor: 4.982

3.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

4.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

Review 5.  Current situation and prospects of newborn screening and treatment for Phenylketonuria in China - compared with the current situation in the United States, UK and Japan.

Authors:  Lin Mei; Peipei Song; Norihiro Kokudo; Lingzhong Xu; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2013-11

6.  Tyrosine monitoring in children with early and continuously treated phenylketonuria: results of an international practice survey.

Authors:  Rachael Sharman; Karen A Sullivan; Ross McD Young; James J McGill
Journal:  J Inherit Metab Dis       Date:  2010-09-30       Impact factor: 4.982

7.  Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria.

Authors:  Erin L MacLeod; Murray K Clayton; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2010-04-14       Impact factor: 4.797

8.  Protein substitutes for phenylketonuria in Europe: access and nutritional composition.

Authors:  M J Pena; M F de Almeida; E van Dam; K Ahring; A Bélanger-Quintana; K Dokoupil; H Gokmen-Ozel; A M Lammardo; A MacDonald; M Robert; J C Rocha
Journal:  Eur J Clin Nutr       Date:  2016-04-27       Impact factor: 4.016

9.  Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes.

Authors:  Erin L MacLeod; Sally T Gleason; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2009-08-08       Impact factor: 4.797

Review 10.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.